Until now, there have been various methods for screening for PCa biomarkers, such as computed tomography (CT), MRI/TRUS fusion guided biopsies, prostate-specific antigen (PSA) test, NMR profiling of metabolites, etc. [2,3]. This evidence concerns the gene KLK3 and posterior cortical atrophy.